[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629222":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Yonsei University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"zastaprazan 20mg","EXPERIMENTAL","Participants receive zastaprazan 20mg and Placebo matching Pariet 10mg tablet 10mg.",[13],"Drug: Rabeprazole",{"label":15,"type":10,"description":16,"interventionNames":17},"Pariet 10mg","Participants receive Pariet 10mg and Placebo matching zastaprazan 20mtablet 10mg.",[18],"Drug: Zastaprazan",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Zastaprazan","Participants will receive Zastaprazan \\[20 mg\\] orally once daily for \\[6 month\\] in addition to standard dual antiplatelet therapy (DAPT) including clopidogrel (75 mg\u002Fday).",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Rabeprazole","Participants will receive Rabeprazole \\[10 mg\\] orally once daily for \\[6month\\] in addition to standard dual antiplatelet therapy (DAPT) including clopidogrel (75 mg\u002Fday).",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Yongcheol Kim, MD, PhD","CONTACT","+82-031-5189-8967","yongcheol@yuhs.ac",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":25,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Yongin Severance Hospital, Yonsei University","RECRUITING","Yongin-si","Gyeonggi-do","16995","South Korea",{"type":45,"coordinates":46},"Point",[47,48],127.08042,37.29686,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":53,"phoneExt":25,"email":35},"Yongcheol Kim, MD","+823151898967",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Yongcheol Kim","Clinical Associate Professor",[59],{"name":60,"class":61},"Jeil Pharmaceutical Co., Ltd.","INDUSTRY","100629222","phase-4-effect-of-zastaprazan-on-platelet-reactivity-of-clopidogrel-after-percutaneous-coronary-intervention-100629222",false,"NCT07471867","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention: A Randomized Double-Blind Pilot Study (EZ-STAR)","EZ-STAR","Inclusion Criteria:\n\n1. Age 19 years or older at the time of providing informed consent.\n2. Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.\n3. Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.\n4. Patients who have voluntarily provided written informed consent to participate in this clinical study.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to P-CABs, PPIs, benzimidazoles, aspirin, clopidogrel, or any of the excipients in the study drugs.\n2. History of or planned surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, acid suppression surgery, or gastric mucosal resection. (However, patients who have undergone simple perforation repair of the stomach or duodenum, appendectomy, cholecystectomy, hysterectomy, or endoscopic\u002Flaparoscopic resection of benign tumors are eligible).\n3. Diagnosis of Zollinger-Ellison syndrome or inflammatory diseases (e.g., pancreatitis, or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis).\n4. Currently receiving HIV protease inhibitors (atazanavir, nelfinavir) or rilpivirine-containing products.\n5. Abnormal blood chemistry values within 4 weeks prior to screening: AST, ALT, ALP, or total bilirubin \\> 3 times the upper limit of normal (ULN). Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m², calculated using the IDMS-traceable MDRD equation.\n6. Recent Medication Use: Use of medications expected to affect the study results, such as P2Y12 inhibitors (other than the prescribed clopidogrel), within 2 weeks prior to baseline.\n7. Pregnant or lactating women, or women with a positive pregnancy test.\n8. Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.","ALL","19 Years",{"count":73,"type":74},100,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.",[80],"Chronic Coronary Syndrome",[80,82],"zastaprazan","2026-04-22",{"date":85,"type":86},"2026-04-24","ACTUAL",{"date":88,"type":86},"2026-04-02",{"date":90,"type":74},"2028-07-12",{"name":5,"class":6},1]